464 related articles for article (PubMed ID: 11412836)
21. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.
Cumming P; Boyes BE; Martin WR; Adam M; Ruth TJ; McGeer EG
Biochem Pharmacol; 1987 Aug; 36(15):2527-31. PubMed ID: 3111485
[TBL] [Abstract][Full Text] [Related]
22. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Männistö PT; Tuomainen P; Tuominen RK
Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
[TBL] [Abstract][Full Text] [Related]
23. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
[TBL] [Abstract][Full Text] [Related]
24. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
Törnwall M; Tuomainen P; Männistö PT
Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
[TBL] [Abstract][Full Text] [Related]
25. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
26. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Reches A; Fahn S
Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
[TBL] [Abstract][Full Text] [Related]
27. Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum.
Reches A; Jiang D; Fahn S
Biochem Pharmacol; 1982 Nov; 31(21):3415-8. PubMed ID: 7150363
[TBL] [Abstract][Full Text] [Related]
28. Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.
Reches A; Jiang D; Fahn S
Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):34-7. PubMed ID: 7121609
[TBL] [Abstract][Full Text] [Related]
29. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd KG; Davidson L; Hornykiewicz O
J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
[TBL] [Abstract][Full Text] [Related]
30. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
[TBL] [Abstract][Full Text] [Related]
31. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.
Waldmeier PC; Baumann PA; Feldtrauer JJ; Hauser K; Bittiger H; Bischoff S; von Sprecher G
Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):305-11. PubMed ID: 1980718
[TBL] [Abstract][Full Text] [Related]
32. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
[TBL] [Abstract][Full Text] [Related]
33. L-DOPA exacerbates amphetamine-induced dopamine depletion.
Myers CS; Witten M; Yu YL; Wagner GC
Mol Chem Neuropathol; 1998 Feb; 33(2):81-97. PubMed ID: 9565967
[TBL] [Abstract][Full Text] [Related]
34. Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum.
Gołembiowska K; Dziubina A
Brain Res; 2004 Feb; 998(2):208-17. PubMed ID: 14751592
[TBL] [Abstract][Full Text] [Related]
35. Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: time course and time-dependent interactions with amfonelic acid.
Steranka LR
Brain Res; 1982 Feb; 234(1):123-36. PubMed ID: 7059818
[TBL] [Abstract][Full Text] [Related]
36. [Microdialysis study of tolcapone effect during blockage of neuronal dopamine reuptake caused by GBR-12909].
Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Li IH; Mannisto PT
Eksp Klin Farmakol; 1997; 60(5):8-10. PubMed ID: 9483396
[TBL] [Abstract][Full Text] [Related]
37. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
Männistö PT; Tuomainen P
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
[TBL] [Abstract][Full Text] [Related]
38. [Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Mannisto PT
Biull Eksp Biol Med; 1998 Feb; 125(2):168-71. PubMed ID: 9559129
[No Abstract] [Full Text] [Related]
39. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Rose S; Jenner P; Marsden CD
Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
Silveira P; Vaz-da-Silva M; Almeida L; Maia J; Falcão A; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):603-9. PubMed ID: 14517707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]